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The phosphate carrier has been isolated from beef heart mitochondria in the presence of cardiolipin and 
reconstituted in asolectin vesicles. It has been found that 100 PM doxorubicin and 1OOpM Br-daunomycin 
inhibit the unidirectional phosphate uptake in the reconstituted liposomes to the same extent as N- 
ethylmaleimide. The inhibition by Br-daunomycin is not due to covalent interaction with the carrier. The 
specific interaction between doxorubicin and cardiolipin is responsible for the inhibition of the phosphate 
carrier. Br-daunomycin interacts with 3 mitochondrial proteins of apparent iWr -45000, -35000 and 
-30000. 
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1. INTRODUCTION 
The Pi-carrier catalyzes the electroneutral 
transport of Pi through the inner mitochondrial 
membrane (review [l]). The transport is inhibited 
by SH-reagents like NEM, mersalyl and p- 
chloromercuribenzoate. The carrier has been 
isolated using non-ionic detergents and 
chromatography on hydroxylapatite/celite [2] and 
on mersalyl-ultrogel [3]. The purified fraction con- 
tains 4-5 protein bands having M, ranging from 
34500 to 30000 [4]. Purification of the carrier to 
homogeneity has been achieved by using an 
organomercurial agarose column [5]. It has also 
been demonstrated that the Pi-carrier has an essen- 
tial requirement for cardiolipin [6]. Cardiolipin is 
necessary for full activity of the carrier and to pre- 
vent its inactivation during the extraction from 
mitochondria with Triton X-l 14. 
Abbreviations: Pi, inorganic phosphate; NEM, N- 
ethylmaleimide; Tris, tris(hydroxymethyl)aminometh- 
ane; Pipes, 1,4-piperazinediethanesulfonic a id; EDTA, 
ethylenediaminetetraacetic acid; HEPES, 4-(2-hydro- 
xyethyl)-1-piperazineethanesulfonic acid; TID, 3- 
(trifluoromethyl)-3-(m-[1z5I]iodophenyl)diazirine 
The anthracycline antibiotic doxorubicin (fig. 1) 
apparently segregates membrane cardiolipin in a 
separate phase, making it inaccessible to 
cytochrome c oxidase incorporated into 
cardiolipin-containing liposomes [7]. Doxorubicin 
forms specific complexes with negatively charged 
phospholipids [8]. The association constant of the 
complex doxorubicin-cardiolipin has been 
calculated to be 1.6 x lo6 M-i. 
Here, the effect of doxorubicin and Br- 
daunomycin on the transport activity of the Pi- 
carrier reconstituted in asolectin liposomes has 
been investigated. Both drugs inhibit the unidirec- 
tional Pi-uptake to the same extent as NBM. 
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Fig.1. Molecular structure of doxorubicin and Br- 
daunomycin. 
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2. MATERIALS AND METHODS 3. RESULTS AND DISCUSSION 
Hydroxylapatite (Bio-Gel HTP) was from Bio- 
Rad (Richmond CA); Celite 535 (Johns Meville) 
from Roth (Karlsruhe); cardiolipin from P-L 
Biochemicals (Milwaukee IL); soybean asolectin 
from Associated Concentrates (New York NY); 
Triton X-114, Amberlite XAD-2 and Dowex AG 
l-X8 from Fluka AG (Buchs); NEM from Sigma 
(St Louis MO); mersalyl from Mann Res. Labs 
(New York NY); doxorubicin and Br-daunomycin 
were generous gifts of Farmitalia-Carlo Erba 
(Milano) . 
Beef heart mitochondria were prepared as in [9], 
and stored frozen at - 80°C. They were solubilized 
at 20 mg/ml in a buffer containing 20 mM KCl, 
10 mM Tris, 10 mM Pipes, 1 mM EDTA, 1 mg 
cardiolipin/ml, 2.5% Triton X-114 and enough 
KOH to bring the pH to 6.5, using the procedure 
in [lo] with slight modifications. After 30 min the 
suspension was centrifuged for 30 min at 100000 x 
g. The supernatant was adsorbed on a hydrox- 
ylapatite/celite (1 : 1, w/w) column (Pasteur 
pipette, containing -600 mg dry material) and 
eluted with 1 ml detergent-free xtraction buffer 
diluted 1: 1 (v/v) with doubly distilled water. The 
pH was adjusted to 8 with KOH. Asolectin 
liposomes were prepared essentially as in [2], in a 
buffer containing 50 mM KCl, 20 mM Tris, 1 mM 
EDTA and enough HEPES to raise the pH to 8 at 
2°C. 100 ~1 of the column eluate were mixed with 
1 ml sonicated asolectin, frozen in liquid Nz, thaw- 
ed in water and sonicated for 20 s. Triton X-l 14 
was removed using Amberlite XAD-2 beads in a 
batch system for 90 min at 2’C. The unidirectional 
Pi-uptake was started by the addition of aliquots 
of HCl adequate to adjust the external pH from 8 
to 6.5, and of 1 mM KPi, to 250 ,ul of reconstituted 
liposomes [l 11. The reaction was stopped by the 
addition of mersalyl. Free Pi was removed as in 
[2]. The column eluate was extracted with 1 ml 
chloroform and 150~1 of the water phase were 
analyzed calorimetrically for Pi [12]. All opera- 
tions were performed at 5°C. Protein was deter- 
mined by a biuret procedure [ 131 or as in [ 141 in the 
presence of 0.5% sodium dodecylsulfate. Sodium 
dodecylsulfate-polyacrylamide gel electrophoresis 
was performed as in [15]. 
Table 1 shows the Pi-uptake mediated by the Pi- 
carrier in reconstituted asolectin liposomes. 
Asolectin contains up to -25% of the total lipid Pi 
as cardiolipin, an amount which is adequate for 
full stimulation of Pi-uptake. The uptake shows a 
rapid initial phase, which reaches aturation within 
2 min under the experimental conditions (not 
shown). The uptake is limited by the dissipation of 
the pH gradient, owing to the electroneutral nature 
of the Pi-carrier (Pi/H+ symport or Pi/OH- an- 
tiport). Addition of lO/rg NEM/mg protein to 
mitochondria prior to their solubilization inhibits 
the reconstituted Pi-carrier. If added after 
reconstitution, the effect of NEM becomes less evi- 
dent, possibly due to the higher lipid to protein 
ratio in liposomes. Mersalyl was also able to in- 
hibit the Pi-carrier, albeit at higher concentrations 
than in intact mitochondria. From these inhibition 
experiments it may be concluded that the orienta- 
tion of the Pi-carrier in the reconstituted liposomes 
is uniform or, alternatively, that the essential SH- 
groups are accessible from both sides of the car- 
rier. Table 1 shows that 10 /IM doxorubicin inhibit 
the uptake of Pi to the same extent as NEM does. 
Since it has been shown that doxorubicin forms 
stable complexes with cardiolipin [S], and since the 
Pi transport activity is very sensitive to the 
presence of cardiolipin in the immediate vicinity of 
Table 1 
Inhibition of the unidirectional Pi-uptake mediated by 
the Pi-carrier econstituted in asolectin liposomes 
Addition Pi-uptake 
(umol.15 s-‘.mg 
prot . - ‘) 
None 39 
NEM (10 /cg/pg protein) 12 
Mersalyl (100 pg/pg protein) 13 
Doxorubicin (100 /IM) 8 
Br-daunomycin (100 FM) 12 
NEM (10 /rg/mg protein)* 10 
a NEM was added to the mitochondria prior to 
solubilization 
The uptake was stopped after 15 s; experimental 
conditions were as in section 2 
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Fig.2. Concentration-dependent inhibition of the Pi- 
uptake in reconstituted liposomes by doxorubicin (A) 
and Br-daunomycin (B). The inhibitors were added to 
the liposomes immediately prior to starting the uptake 
reaction, which was stopped after 15 s; conditions are 
described in section 2. 
the Pi-carrier, it is very probable that this inhibi- 
tion is due to the binding of cardiolipin by dox- 
orubicin. The possibility that the inhibition by 
doxorubicin reflects the binding of the drug to the 
Pi-carrier itself has been tested using the highly 
reactive brominated doxorubicin analogue Br- 
daunomycin (fig.3). When added to the 
reconstituted liposomes, the analogue inhibits the 
uptake of Pi to the same extent as doxorubicin 
(table 1, fig.2). However, calorimetric tests in- 
dicate that the Pi-carrier isolated from mitochon- 
dria treated with Br-daunomycin is free of the in- 
hibitor, and is fully active after reconstitution in 
liposomes. In addition, it can still be fully inhibited 
by doxorubicin, Br-daunomycin, NEM or mersalyl 
(not shown). This supports the tentative conclu- 
sion reached before that doxorubicin and Br- 
daunomycin react specifically with cardiolipin 
molecules essential for the Pi-carrier. 
It is known that the Pi-carrier has a pronounced 
hydrophobic character, and is one of the few pro- 
teins which binds the hydrophobic probe TID in 
the inner mitochondrial membrane (unpublished). 
It would thus not be surprising if it would form ag- 
gregates and lose activity, when solubilized in the 
absence of cardiolipin. A possible role of car- 
diolipin could thus be the maintenance of the ac- 
tive carrier structure, which has been proposed to 
be a dimer [ 161. It may also be noted here that the 
Fig.3. Sodium dodecylsulfate-polyacrylamide gel electrophoresis of mitochondria incubated with increasing amounts 
of Br-daunomycin (50, 100, 200, 3OOpM, respectively, lanes l-4) for 5, 10 min at room temperature in isoosmotic 
medium at pH 7.4. Left panel: Coomassie blue stain. Right panel: fluorography. The labeled bands have apparent M, 
of -45000 (A), -35000 (B) and -30000 (C). The ADP/ATP translocator is labeled by the arrows. 
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Pi-carrier is a basic protein (p1 = 8, unpublished). 
Its affinity for cardiolipin could thus be explained 
by the formation of ion pairs between positively 
charged amino groups on the carrier molecules and 
negatively charged phosphate residues of 
cardiolipin. 
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